Regeneron (REGN) Misses Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Regeneron Pharma (REGN) Price Target Raised to $410 at RBC
November 4, 2014 3:28 PM ESTRBC Capital maintained an Outperform rating on Regeneron Pharma (NASDAQ: REGN) and raised its price target to $410.00 (from $373.00). Comments follow Q3 results. Analyst Adnan Butt said he was a buyer of pullbacks.
"While ramp from DME did not materialize, the... More
Regeneron Pharma (REGN) Price Target Raised to $455 at Deutsche Bank
November 4, 2014 1:39 PM ESTDeutsche Bank reiterated a Buy rating on Regeneron Pharma (NASDAQ: REGN) and raised its price target to $455.00 (from $425.00). The change follows Q3 results. Analyst Robyn Karnauskas sees major upside in the stock next year.
"Eylea US sales for 3Q missed expectations at... More
